Viking Therapeutics $VKTX, Structure Therapeutics $GPCR and Altimmune $ALT: The Next Obesity Drug Race

Publication date: May 9, 2026
Coverage: Obesity, oral GLP-1s, dual agonists, MASH, late-stage biotech catalysts and competitive impact.
Companies covered: Viking Therapeutics ($VKTX), Structure Therapeutics ($GPCR), Altimmune ($ALT).
Important note: For information and analysis only. Not medical advice and not a buy, sell or hold recommendation. Treatment choices belong to licensed clinicians; investment decisions belong to each reader’s own process, risk tolerance and due diligence.

Lead thesis

The obesity-drug market has moved from discovery excitement into commercial combat. That is the central change investors have to absorb. In 2023 and 2024, it was still possible to build a strong biotech story around the idea that a company had an obesity asset with meaningful weight-loss data. In May 2026 that is no longer enough. The benchmark is no longer theoretical. Patients can already get injectable semaglutide, injectable tirzepatide, oral semaglutide and oral orforglipron in the U.S. market, while older weight-management drugs still occupy price-sensitive, generic or non-incretin niches. Novo Nordisk’s Wegovy pill was approved in December 2025 as an oral GLP-1 option for weight management, and Eli Lilly’s Foundayo, orforglipron, was approved in April 2026 as a once-daily oral GLP-1 pill that Lilly says can be taken without food or water restrictions. Those approvals make the next phase more difficult, but also more valuable, because they validate patient demand for convenience and scale. [3] [1] [2]

That is why Viking Therapeutics, Structure Therapeutics and Altimmune should be analyzed together, but not flattened into the same trade. Viking is the late-stage dual incretin contender, with subcutaneous VK2735 already in a large Phase 3 obesity program and an oral formulation preparing for Phase 3. Structure is the purest oral-small-molecule obesity challenger, with aleniglipron now carrying one of the strongest independent oral Phase 2 profiles in the field. Altimmune is the differentiated liver-metabolic story: pemvidutide has weight-loss biology and prior obesity development history, but Altimmune’s current official development focus is MASH and serious liver diseases, with AUD and ALD as additional active programs. The three names sit inside the same metabolic revolution, but they are trying to win different pieces of it.

The practical investor question is not simply, “Which drug causes the most weight loss?” That question matters, but it is too narrow. The better question is, “Which asset can still matter after Novo and Lilly have already commercialized both injections and pills?” Once that is the question, the analysis changes. Viking must prove that dual GLP-1/GIP optionality, oral-plus-injectable flexibility and possible maintenance regimens create a profile large pharma would still want. Structure must prove that aleniglipron is not merely another oral GLP-1, but a commercially credible oral backbone with strong efficacy, manageable titration and enough scale logic to survive against approved pills. Altimmune must prove that pemvidutide can occupy a liver-first lane where glucagon biology matters, MASH endpoints matter and weight loss is a supporting advantage rather than the whole thesis.

The medicine cabinet already exists

The first point for readers is simple: these three companies are not entering a market with no current medicines. They are entering a market that already has several layers of treatment. The first layer is the older obesity-drug toolkit: orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, short-term sympathomimetic agents such as phentermine, and rare-disease agents such as setmelanotide. The second layer is the incretin blockbuster layer: Wegovy, Zepbound and related diabetes-branded cousins such as Ozempic and Mounjaro, which have shaped real-world expectations even where the exact label differs by product and geography. The third layer is the new oral incretin layer: Wegovy pill and Foundayo. The fourth layer is the liver-metabolic layer, where Rezdiffra is already the key MASH-approved reference point and where GLP-1-based agents are increasingly being tested or positioned for liver outcomes. [4] [5] [7]

That existing medicine cabinet matters for four reasons. First, physicians already know what meaningful weight loss looks like in practice. Second, payers already know how expensive broad obesity coverage can become. Third, patients now have a real preference set: weekly injection, daily pill, brand familiarity, side-effect tolerance, price, coverage, direct-to-consumer access and telehealth convenience. Fourth, new entrants no longer get paid just for joining the category. They need to earn their place with durability, tolerability, cost logic, manufacturing logic, differentiated comorbidity data, or a highly targeted indication.

Current anti-obesity and metabolic medicines in active use

This table should not be read as a treatment recommendation. It is a market map. It shows why the next obesity-drug race is not a single lane. A patient with obesity and no diabetes, a patient with obesity and type 2 diabetes, a patient with obesity and obstructive sleep apnea, a patient with MASH and F2/F3 fibrosis, a patient who refuses injections, a patient who cannot tolerate nausea, and a patient whose payer demands step therapy may all end up in different commercial pools. That is where the smaller biotechs may still find room.

The current treatment base changes the investment bar

A pre-2025 obesity biotech could argue that a strong mid-stage weight-loss signal was enough to create strategic scarcity. In May 2026, scarcity is more specific. Scarcity may still exist in oral dual agonism, in better maintenance dosing, in fixed-dose oral combinations, in liver-focused metabolic therapy, in safer or more tolerable titration, in lean-mass preservation, in lower manufacturing complexity, or in non-U.S. expansion where cold-chain logistics and injection aversion can matter. But scarcity no longer exists in “a GLP-1 product that helps people lose weight.” Novo and Lilly have already commercialized that category at massive scale.

The commercial incumbents also now have a financial flywheel. Lilly reported first-quarter 2026 revenue of $19.8 billion, with Mounjaro at $8.7 billion and Zepbound at $4.16 billion. That matters because it shows how much cash the leader can recycle into manufacturing, trials, payer contracting, direct channels and next-generation programs. It also means that any smaller company trying to go independent must think realistically about the cost of commercializing into a category where the largest players can spend aggressively. [16]

Novo’s Wegovy pill approval also changes the oral narrative. The original speculative story around oral obesity was that a pill could open the market to needle-averse patients and make broad adoption easier. That thesis has not disappeared; if anything, it has been validated. But once validated by a large incumbent, it becomes harder for a small company to capture the first-mover premium. A company such as Structure now has to argue for aleniglipron on relative profile, not merely on route. Viking’s oral formulation faces the same problem, although Viking can add a different claim: if both its injectable and oral VK2735 succeed, it could eventually offer a single-molecule transition from induction to maintenance or from injection to tablet. That is still strategically interesting, but it must be proven.

Market forecasts remain large enough to keep the race attractive. Morgan Stanley Research expects the global market for GLP-1 drugs for type 2 diabetes and obesity to reach about $190 billion by 2035, while Reuters has reported more cautious 2030 obesity-drug estimates from some analysts after price pressure and changing use patterns were factored in. The crucial point is not whether the exact number is $105 billion, $150 billion, $190 billion or something else. The crucial point is that even a small durable share can be economically meaningful, but only if the product earns access and persistence in a market where price erosion is no longer theoretical. [17] [18]

How new competition could affect the three challengers

The likely impact of competition is asymmetric. Viking and Structure face the most direct pressure from approved obesity drugs because their lead value proposition is closer to mainstream weight management. Altimmune faces indirect pressure from obesity drugs, but direct pressure from MASH and metabolic-liver competitors. The table below gives a practical, directional model. It is not a forecast of revenue, and it should not be treated as company guidance. It is a directional estimate of where competition is most likely to change the risk-reward balance.

For Viking, competition probably lowers the value of the plain-vanilla obesity thesis but increases the value of the dual-formulation thesis. If VK2735 simply looks like another high-quality injectable, the market will ask why it deserves strategic premium pricing in a field already led by Lilly and Novo. If VK2735 can show strong Phase 3 efficacy, manageable tolerability, optional maintenance schedules and a credible oral path, the asset remains strategically relevant because few companies can claim both injectable and oral versions of the same dual GLP-1/GIP molecule. The difference between those two outcomes is enormous.

For Structure, competition cuts deepest. Aleniglipron’s Phase 2 data are impressive, but the market context changed faster than the company. In a world without approved oral obesity drugs, aleniglipron could have been valued mainly as proof that oral small molecules can work. In today’s world, the question is whether it can outperform or meaningfully differentiate from Foundayo and Wegovy pill. That does not mean the thesis is broken. Oral share may become large; Reuters has reported Structure’s view that oral weight-loss pills could capture 25% to 50% of the GLP-1 obesity market by 2030. If that view is even partly right, a strong oral challenger can still matter. But the bar is now efficacy plus tolerability plus dosing practicality plus commercial timing. [19]

For Altimmune, competition is more nuanced. More obesity drugs can reduce the perceived value of pemvidutide as a standalone weight-loss asset, but that is no longer the cleanest frame for the company. Altimmune previously aligned with the FDA on a potential Phase 3 obesity program, yet its current official communications position pemvidutide around MASH and serious liver diseases, with AUD and ALD as additional active programs. If pemvidutide proves strong enough in MASH, especially on biopsy-based endpoints and fibrosis-related measures, it may compete in a different lane. Rezdiffra is already approved and validates the MASH market, but it also raises the bar. Semaglutide, tirzepatide and other metabolic drugs may also push into liver disease. Altimmune’s best chance is not to be another obesity shot; it is to be a liver-metabolic therapy whose weight-loss, liver-fat and glucagon-driven biology work together.

A practical impact estimate by company

The cleanest way to estimate competitive impact is to separate category expansion from share compression. Category expansion is positive for everyone: more diagnosed patients, more clinician comfort, more payer infrastructure, more telehealth channels, more public awareness and more investor attention. Share compression is negative: more approved drugs, lower prices, step therapy, payer restrictions, high marketing spend, and less scarcity for assets that are merely “similar.” Every company here receives both effects, but the ratio differs.

Viking Therapeutics: The category expansion benefit is high because Phase 3 obesity assets remain rare and strategically valuable. The share-compression risk is also high because the asset is not expected to reach the market before large incumbents have years of commercial experience. A reasonable directional estimate is that competition has already reduced the standalone value of a non-differentiated VK2735 outcome, but it has not destroyed the strategic value of a differentiated VK2735 outcome. If subcutaneous VK2735 delivers durable, clean Phase 3 efficacy and the oral program advances smoothly, competition could even make Viking more valuable to a large partner that lacks a credible dual-formulation approach. If the Phase 3 profile is merely comparable and the oral tolerability is difficult, competition could turn Viking from a premium obesity platform into a good but crowded late-stage asset.

Structure Therapeutics: The category expansion benefit is very high because the world is now clearly ready for oral obesity therapy. The share-compression risk is even higher because the company is no longer early to the oral market. Foundayo and Wegovy pill make aleniglipron’s Phase 3 design crucial. If Structure can confirm 16%-plus placebo-adjusted weight loss with a better titration strategy and low discontinuation, the asset can still be a serious oral contender. If Phase 3 shows less separation, slower durability or class-like discontinuation that cannot be managed, the market may discount it heavily because prescribers already have approved oral options. The estimated impact of competition is therefore binary: category validation helps the bull case, but first-mover loss hurts the base case.

Altimmune: The category expansion benefit is moderate in obesity-adjacent investor attention but potentially high in MASH. The share-compression risk from obesity drugs is moderate, while direct MASH competition is high. Rezdiffra means liver specialists already have a disease-targeted option, and future GLP-1/GIP or GLP-1/glucagon programs could add pressure. Still, Altimmune may be protected by differentiation if pemvidutide continues to show an unusually favorable combination of liver-fat reduction, non-invasive fibrosis-marker improvement, weight loss and tolerability. The estimated competitive impact is therefore less about mass obesity share and more about whether the company can claim a distinct MASH profile. Competition hurts pemvidutide if investors value it as a pure obesity drug. Competition may help if broader metabolic-medicine adoption pushes more MASH patients into active diagnosis and treatment.

What “winning” may mean now

Winning in 2026 does not necessarily mean becoming the next Zepbound. That bar may be unrealistic for most smaller companies. Winning can mean producing a Phase 3 asset attractive enough for a strategic partnership. It can mean owning a high-value subsegment such as oral maintenance after injection-induced weight loss. It can mean becoming a fixed-dose combination backbone. It can mean showing a liver-metabolic benefit profile that creates demand among hepatologists rather than only obesity specialists. It can mean building enough evidence to be acquired before commercial spending becomes overwhelming. In a market this large, a smaller company can win without becoming the market leader.

At the same time, the market will be ruthless toward assets that are not specific about why they exist. “Convenient” is no longer specific. “GLP-1-based” is no longer specific. “Strong Phase 2 weight loss” is no longer specific unless the study duration, titration, discontinuation, population and comparators support a real commercial argument. The next obesity-drug race is not just a science race; it is a design, access, manufacturing, persistence and segmentation race.

How to read the three companies

For investors following the stocks, the cleanest approach is to ask five questions every time new data arrive.

First, does the asset improve the clinical profile, or merely add another version of an existing profile? Second, does the route of administration solve a real patient problem without creating a new adherence problem? Third, does the tolerability profile allow real-world persistence, not just trial completion? Fourth, does the company have enough capital or partnership leverage to reach the next value-creating event without punitive dilution? Fifth, does the asset have a natural commercial home: primary care, endocrinology, obesity medicine, hepatology, cardiology, sleep medicine, telehealth or specialty pharmacy?

Those questions are the reason these three names are not interchangeable. Viking is a scale-up and Phase 3 differentiation story. Structure is an oral efficacy, titration and competitive-timing story. Altimmune is a MASH proof, serious-liver-disease and capital-structure story. The overlap is metabolic disease. The risk is different.

The three-company race after the first GLP-1 wave

Obesity and metabolic disease remain one of the largest and most strategic areas in global biopharma, but the conversation in May 2026 is no longer just about who can produce the biggest headline weight-loss percentage. The field has already moved into a second phase: Novo Nordisk has an approved U.S. Wegovy pill, Eli Lilly has an FDA-approved obesity pill in Foundayo, and both companies already dominate the first commercial wave through blockbuster injectable incretins. That means newer contenders must now prove something more specific: better differentiation, stronger durability, cleaner tolerability, sharper manufacturing logic, clearer patient segmentation, or a more compelling route into adjacent metabolic diseases such as MASH.

That is why Viking Therapeutics, Structure Therapeutics and Altimmune belong in the same strategic conversation but should not be treated as the same stock story. Viking is the closest of the three to the classic “next-generation obesity biotech” setup, built around a dual GLP-1/GIP agonist in both injectable and oral forms. Structure is the purest oral obesity comparison, but it is now chasing a market where oral GLP-1 products are no longer hypothetical. Altimmune is different again: pemvidutide does produce weight loss, but Altimmune’s current official development focus is MASH and serious liver diseases, where glucagon biology could confer a different kind of edge.

The central question, then, is not “Which company has a weight-loss asset?” All three have metabolic assets with weight-loss relevance, but they are not all pursuing the same current development lane. The better question is: which therapeutic direction matters most after the first wave of GLP-1 dominance? A dual incretin that tries to compete closer to Lilly’s category leadership? A once-daily oral small molecule aimed at access, convenience and scale? Or a dual GLP-1/glucagon program that uses weight loss as one part of a broader liver-metabolic strategy?

Executive summary

Viking is the most visible pure-play obesity biotech in this trio. Subcutaneous VK2735 is already in a large Phase 3 obesity program through VANQUISH-1 and VANQUISH-2, both of which are fully enrolled according to Viking’s latest update. Oral VK2735 also matters a great deal: after a December 2025 end-of-Phase 2 meeting, Viking said in April 2026 that it plans to begin Phase 3 development of the oral program in the fourth quarter of 2026. That dual-formulation strategy is the main reason Viking still attracts premium attention despite a more crowded incretin field.

Structure is the cleanest oral metabolic story here, but it is also the company whose competitive frame has changed the most in the last year. The March 2026 ACCESS II readout showed placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg at 44 weeks, plus fewer discontinuations in later studies using a lower 2.5 mg starting dose. That is strong Phase 2 evidence. But commercial reality now looks different than it did when oral GLP-1 was a future category: Lilly’s Foundayo is already approved and Novo’s Wegovy pill is already in market. Structure therefore needs aleniglipron to be not merely oral, but commercially differentiated on efficacy, tolerability, dosing logic, access, or manufacturability.

Altimmune is the differentiated outlier. Pemvidutide is a balanced GLP-1/glucagon dual agonist, and the company’s current official messaging frames it as a serious-liver-disease program rather than a standard obesity franchise. In the IMPACT Phase 2b MASH trial, 24-week data showed statistically significant MASH resolution without worsening of fibrosis, while the 48-week update showed continuing improvements in key non-invasive fibrosis markers such as ELF and LSM, plus continued weight loss at the 1.8 mg dose and a discontinuation rate due to adverse events that remained below placebo. Altimmune also completed financing in April 2026 that management says funds operations through the anticipated 52-week Phase 3 MASH readout.

Quick comparison

The table above draws on the companies’ latest official releases, trial announcements, and ClinicalTrials-related disclosures.

Why the race has entered a second phase

The first phase of the obesity-drug boom was simple to describe: large weight-loss outcomes, enormous demand, and category dominance by Novo Nordisk and Eli Lilly. By May 2026, however, the market is already dealing with second-order questions. Lilly’s first-quarter 2026 revenue growth was led by Mounjaro and Zepbound, while Lilly also highlighted FDA approval of Foundayo, its once-daily obesity pill. Novo, for its part, won U.S. approval for the Wegovy pill in late 2025 and launched it in early 2026. That changes the bar for every smaller company in this space. “Oral” is no longer enough as a thesis by itself.

Mechanistically, GLP-1 receptor agonism remains the foundation. GLP-1 signaling reduces appetite, slows gastric emptying, improves glycemic control and supports weight loss. Dual GLP-1/GIP agonism adds another incretin pathway that has been associated with stronger weight-loss and glycemic effects in the marketed category leader tirzepatide, though the exact balance of GLP-1 versus GIP contribution is still discussed in the literature. GLP-1/glucagon dual agonism pursues a different logic: combine the appetite and glycemic benefits of GLP-1 with glucagon-driven energy expenditure and direct hepatic fat effects, which is why the approach remains especially interesting in MASH and related liver disease.

The route of administration also matters more than it did two years ago. Oral small molecules promise easier use, fewer injection barriers and potentially simpler industrial scaling than peptide injectables, which is why Structure has repeatedly emphasized accessibility and scalability. Lilly’s Foundayo further raised the bar by being approved as a once-daily pill without food or water restrictions, making convenience a concrete commercial benchmark rather than an abstract aspiration.

But this second phase is also about what weight-loss percentages do not tell you. Investors now care more about durability, titration, discontinuation, gastrointestinal burden, patient adherence, manufacturing strategy, cardiometabolic breadth, body-composition effects, liver efficacy and payer acceptability. That is why Structure is running body-composition and switch studies, Viking is running a maintenance-dosing study, and Altimmune is pushing pemvidutide toward MASH and serious liver diseases rather than trying to market it only as another anti-obesity shot.

Cross-trial comparisons remain imperfect, and that warning is especially important here. Viking’s best-known obesity data are still relatively short-duration Phase 2 signals in non-diabetic obesity, Structure’s lead oral dataset runs to 44 weeks with different dose-escalation choices, and Altimmune’s flagship data are in biopsy-confirmed MASH with fibrosis rather than classic obesity-enrollment design. Trial duration, baseline BMI, diabetes status, titration pace, estimated treatment effect definitions and discontinuation handling all differ enough that any cross-program ranking should be described as directional, not definitive.

Viking Therapeutics

Viking is still the most straightforward “next obesity biotech” in this group. The core asset, VK2735, is a dual GLP-1/GIP agonist being developed in both a weekly subcutaneous formulation and an oral tablet formulation. The company’s current profile is defined by scale-up and transition risk: the science has already produced compelling Phase 2 signals, but 2026 and 2027 are now about late-stage proof, operational execution and commercial positioning.

The subcutaneous program is now in the large VANQUISH Phase 3 registration program. Viking’s Phase 3 design calls for two 78-week randomized, double-blind, placebo-controlled obesity studies, one in people with obesity or overweight without type 2 diabetes and one in people with obesity or overweight with type 2 diabetes. The company originally described target enrollments of roughly 4,500 for VANQUISH-1 and 1,100 for VANQUISH-2, and by the April 2026 update both studies were fully enrolled.

The historical efficacy backdrop is why the program remains closely watched. In the Phase 2 VENTURE study, weekly subcutaneous VK2735 produced statistically significant mean weight loss from baseline of up to 14.7% after just 13 weeks, with no sign of plateau, while most gastrointestinal adverse events were mild or moderate and discontinuation rates were described as low and balanced versus placebo. Viking later said cardiometabolic analyses from VENTURE showed improvements in metabolic syndrome and prediabetic status relative to placebo, which helps the asset read as more than just a short-duration weight-loss story.

The oral program is what makes Viking more than a one-shot obesity story. In VENTURE-Oral, a 13-week Phase 2 trial in 280 adults with obesity or overweight plus comorbidity, once-daily oral VK2735 produced statistically significant reductions in body weight up to 12.2% from baseline, with no plateau at 13 weeks. The company also reported an exploratory low-dose maintenance cohort suggesting that weight maintenance may be possible at doses below 30 mg daily, reinforcing management’s idea that patients could potentially move from induction to a maintenance phase on the same molecule.

The tolerability picture for oral VK2735 is encouraging but not frictionless. Viking said 98% of drug-related treatment-emergent adverse events were mild or moderate and 99% of GI-related events were mild or moderate. That said, discontinuations due to adverse events were 20% in VK2735 arms versus 13% on placebo, and overall treatment discontinuation reached 28% versus 18% for placebo. In other words, the oral formulation showed real efficacy, but it did not escape class-like GI tradeoffs. That matters because oral obesity is now a directly commercial category, not merely a pipeline category.

The most important current strategic update is regulatory timing. Viking said in February 2026 that oral VK2735 was expected to begin Phase 3 in the third quarter of 2026, but in the April 2026 first-quarter update the company said that, after completing its end-of-Phase 2 meeting with the FDA in December 2025, it planned to begin oral Phase 3 in the fourth quarter of 2026. That is not a dramatic derailment, but it is a real date shift and investors should treat the latest disclosed target as the operative one.

Viking is also trying to widen the dosing conversation. The company initiated a randomized Phase 1 maintenance-dosing study in October 2025 to explore weekly, every-other-week and monthly maintenance regimens after induction with subcutaneous VK2735. Enrollment was completed in January 2026 and data are expected in the third quarter of 2026. This is strategically important because differentiated maintenance scheduling could matter commercially even if induction efficacy converges across the class.

Financially, Viking remains well funded but its burn has clearly stepped up with late-stage work. At March 31, 2026, the company held $603 million in cash, cash equivalents and short-term investments, down from $706 million at December 31, 2025. First-quarter 2026 R&D expense was $150.2 million, G&A was $14.0 million, and net loss was $158.3 million. Viking did not provide a formal runway statement in the April 2026 release, so any runway estimate from here is inference rather than guidance; the main point is that late-stage spending has materially changed the financial profile.

Viking’s bull case is still strong: it has late-stage scale, true dual-agonist biology, a second oral route, and a maintenance-dosing angle that large pharma could find strategically useful. The base case is that it remains a credible next-generation obesity platform but still needs a commercially compelling Phase 3 readout in a market now shaped by marketed injectables and marketed pills. The bear case is that Phase 3 execution, GI tolerability, schedule drift, and a fast-rising burn rate could compress the strategic premium before registration data arrive.

The biggest unanswered question for Viking is whether VK2735 is differentiated enough. The injectable profile is credible, but the obesity market is no longer rewarding generic “me too, but good” assets. What could make the Phase 3 program commercially compelling would be a combination of strong absolute efficacy, clean tolerability, meaningful durability and a credible maintenance or oral-transition narrative. What could go wrong is simpler: if the asset ends up looking merely competitive in efficacy, class-like in GI burden and capital-intensive to finish, the market may start to view it as an attractive but non-unique asset rather than a premium obesity franchise.

Structure Therapeutics

Structure is best understood as the pre-Phase 3 oral challenger whose scientific case improved while its commercial path became harder. The asset, aleniglipron, is an investigational once-daily oral small-molecule GLP-1 receptor agonist designed as a biased GPCR agonist. The company has spent the last year trying to show that oral small molecules can deliver enough efficacy to matter, while also building a tolerability narrative around lower starting doses and slower titration.

The headline dataset is ACCESS II. In March 2026, Structure reported 44-week topline data showing placebo-adjusted mean weight loss of 16.3% at 180 mg and 16.0% at 240 mg, with no evidence of a weight-loss plateau. That is why aleniglipron has remained one of the strongest independent oral obesity stories: the efficacy is clearly no longer trivial, and the duration is longer than the early oral datasets that used to dominate the category conversation.

The company’s earlier 36-week ACCESS program already framed the direction of travel. In the core Phase 2b ACCESS study, aleniglipron delivered placebo-adjusted weight loss of 11.3% at the 120 mg dose, while ACCESS II showed up to 15.3% placebo-adjusted weight loss at 36 weeks with 240 mg. The problem in those earlier studies was tolerability and discontinuation: the 36-week ACCESS dataset carried a mean AE-related discontinuation rate of 10.4% across active arms.

Structure’s answer has been titration redesign. The March 2026 update showed that in the ACCESS OLE and body-composition studies, both of which used a lower 2.5 mg starting dose, AE-related discontinuations fell to 2.0% and 3.4%, respectively, at a median exposure of 20 weeks. ACCESS II itself also looked better late in treatment, with only one AE-related discontinuation among participants who reached 120 mg or higher from weeks 28 to 44. The message from management is straightforward: aleniglipron’s commercial viability depends less on proving that the molecule works, and more on proving that it can be titrated in a way patients will stay on.

The commercial context is now the crucial issue. When aleniglipron’s early obesity program started, the strategic question was whether oral obesity could become real. By May 2026, that question has been answered. Novo’s Wegovy pill is approved and launched in the U.S., and Lilly’s Foundayo is FDA-approved for obesity. Foundayo is especially relevant because Lilly positions it as a once-daily oral GLP-1 that can be taken any time of day without food or water restrictions, and the company reported 12.4% weight loss at the highest dose in ATTAIN-1 among those who stayed on treatment. Structure is therefore no longer selling “oral obesity exists”; it is selling “another oral option can still win on profile.”

That competition cuts both ways. On the positive side, Lilly and Novo may have validated payer, physician and patient demand for oral obesity treatment, which helps the category. On the negative side, category validation means Structure has lost the first-mover premium it might once have commanded. Aleniglipron must now win a more specific argument, likely centered on efficacy positioning, tolerability optimization, combination flexibility or manufacturing economics. The company itself repeatedly emphasizes accessibility, scalability and combinability as part of the strategic thesis.

Phase 3 timing remains one of the biggest near-term issues. In December 2025, Structure said the Phase 3 program could begin by mid-2026. In March 2026, after the ACCESS II update, the language shifted to second-half 2026, with a Type B end-of-Phase 2 meeting scheduled for the second quarter. In the May 7, 2026 first-quarter update, the company tightened guidance to a Phase 3 start in the third quarter of 2026, while also guiding ACCESS OLE data for Q3 and body-composition plus T2D/obesity data for Q4. That is a useful catalyst stack, but it also means investors still need to track whether “Q3” turns into an actual study start rather than another moveable target.

Financially, Structure is the strongest balance-sheet story in this trio by a wide margin. Cash, cash equivalents and short-term investments were $1.5 billion at March 31, 2026, and management said that amount should fund operations and key milestones through the end of 2028. The same release reported first-quarter 2026 R&D expense of $66.5 million, G&A expense of $22.9 million and net loss of $76.0 million. Management also noted the company received a $100 million upfront license fee in the quarter tied to patents covering a different class of oral GLP-1 agonists, which modestly improves the cash story further.

That cash profile matters strategically. Unlike many obesity biotechs, Structure does not look forced into a near-term financing corner while preparing a registrational program. The main financial caveat is that management explicitly said its runway excludes pre-commercialization costs, including commercial manufacturing. That is not a flaw, but it is a reminder that Phase 3 readiness and commercial readiness are not the same thing.

The bull case for Structure is that aleniglipron has emerged as one of the most credible oral obesity candidates outside big pharma, with a Phase 2 dataset that is strong enough to keep “best-in-class oral” in the discussion. The base case is that the science remains promising, but valuation and upside are capped until Phase 3 design and head-to-head commercial differentiation become clearer. The bear case is that tolerability, discontinuation, or simple competitive timing against already-approved oral GLP-1s could make the asset look good but not disruptive.

The most important question for investors is whether aleniglipron is still differentiated enough after Foundayo and Wegovy pill. The strongest answer Structure can give is not ideology but execution: strong longer-term efficacy, visibly lower discontinuation with the 2.5 mg start, clear Phase 3 design, and evidence that oral-adherence advantages translate into real commercial segmentation. Without that, the market may conclude that aleniglipron is scientifically impressive but commercially late.

Altimmune

Altimmune is the name in this group that should not be forced into a simplistic “weight-loss stock” framework. The company’s current official communications describe pemvidutide as a therapy for serious liver diseases, especially MASH, with AUD and ALD as additional active programs. The investment thesis increasingly hinges on whether GLP-1/glucagon biology can produce a more differentiated liver-metabolic profile than pure obesity assets can offer. The obesity read-through still matters, because pemvidutide has shown weight-loss effects and previously had an obesity development path, but it is no longer the center of gravity in the company’s current disclosed development priorities.

The 24-week IMPACT Phase 2b MASH data were the key proof-of-concept event. In June 2025, Altimmune reported that pemvidutide met its primary endpoint, with MASH resolution without worsening of fibrosis achieved in 59.1% and 52.1% of patients at the 1.2 mg and 1.8 mg doses, versus 19.1% for placebo in an ITT analysis. Fibrosis improvement without worsening of MASH reached 31.8% and 34.5% versus 25.9% for placebo, while liver-fat reduction, ALT improvement and non-invasive fibrosis markers also improved materially. Weight loss at 24 weeks was 5.0% and 6.2% for the active doses, and discontinuation due to adverse events remained extremely low at 0.0% and 1.2%, below placebo.

The December 2025 48-week update is what made the story more investable. Altimmune reported continuing improvement in key non-invasive fibrosis markers, especially ELF and LSM, with the 1.8 mg dose showing further weight loss to 7.5% and no evidence of plateau. Liver fat, ALT and cT1 also improved meaningfully, and discontinuation due to adverse events was still only 1.2% at the 1.8 mg dose versus 3.5% for placebo. That combination — fibrosis-related marker improvement, ongoing weight loss, and unusually favorable discontinuation versus placebo — is the heart of the pemvidutide differentiation case.

Mechanistically, the glucagon component is the reason Altimmune belongs in a different bucket. In its MASH-focused review literature and company materials, the rationale is consistent: GLP-1 provides appetite suppression and weight loss, while glucagon may increase energy expenditure and directly mobilize hepatic fat, potentially helping on liver-fat reduction, inflammation and fibrosis. That same glucagon biology is also what keeps the program differentiated rather than simply being another GLP-1 entrant. The risk, of course, is that differentiation can also mean a narrower comfort zone for investors and clinicians if the final dataset is less clean than hoped.

The regulatory path has become clearer in MASH. Altimmune said it completed a productive end-of-Phase 2 meeting with the FDA, secured Breakthrough Therapy Designation for pemvidutide in MASH, and aligned on a registrational Phase 3 design evaluating multiple doses over a 52-week treatment period with biopsy-based endpoints to support potential accelerated approval. As of May 9, 2026, the company still guides only that Phase 3 initiation is planned for 2026; it has not yet provided the sharper quarter-level timing that Viking and Structure have given for their next major study-start events.

It is also important to separate Altimmune’s historical obesity development path from its current active positioning. In late 2024, the company announced successful completion of an end-of-Phase 2 meeting with the FDA for pemvidutide in obesity and described a potential Phase 3 obesity program. However, the company’s latest official disclosures now describe pemvidutide around MASH, AUD and ALD, and the Phase 3 program being prepared in 2026 is the pivotal MASH program. That distinction matters for investors: pemvidutide’s weight-loss biology remains strategically relevant, but Altimmune should not be framed as currently advancing a lead Phase 3 obesity indication in the same way as Viking or Structure.

The financial story is both improved and more complex. At December 31, 2025, Altimmune had $274 million in cash, cash equivalents and short-term investments. Management then said that as of February 28, 2026, cash and cash equivalents were approximately $340 million after a $75 million January registered direct offering and $8 million raised through the ATM facility. In April 2026, Altimmune then closed a much larger $225 million public offering, plus an additional warrant tranche tied to up to 75 million shares that management said extends runway through the anticipated 52-week Phase 3 MASH data readout.

That funding package reduces near-term existential financing risk, but it does not remove dilution risk. The April financing included 64.25 million common shares, 10.75 million pre-funded warrants and accompanying warrants covering up to 75 million shares or pre-funded warrants, exercisable until the earlier of five years or 45 days after a successful Phase 3 MASH readout. This is an unusually consequential capital structure feature and one reason the stock’s risk-reward looks different from a clean-cash biotech story.

The latest verified Altimmune operating figures available on May 9, 2026 were still from the March 2026 full-year update: fourth-quarter 2025 R&D expense of $18.4 million, G&A expense of $10.5 million, quarterly net loss of $27.4 million, and year-end debt that included a $34.3 million noncurrent term loan. The next official update is scheduled for May 13, 2026.

The bull case for Altimmune is that pemvidutide becomes one of the more differentiated MASH assets in development because it hits both metabolic and liver-specific dimensions while maintaining a favorable tolerability profile. The base case is that the Phase 2 story looks promising, but the market continues to discount the company until Phase 3 initiation and funding questions are fully stabilized. The bear case is that MASH remains a difficult regulatory and clinical field, and that successive financings plus warrant overhang could keep equity upside capped unless Phase 3 signals are exceptional.

For valuation framing, the most important conceptual point is this: pemvidutide is best understood as a metabolic-liver platform first, an obesity-adjacent weight-loss asset second. That difference matters because it creates a separate commercial lane, but it also means the stock is less cleanly mapped to the mass obesity market than Viking or Structure. Investors who want a pure obesity lane may find that frustrating. Investors who think the next leg of metabolic therapeutics expands through liver disease may find it exactly why Altimmune belongs in the discussion.

Side-by-side comparison

Mechanism comparison in plain language

GLP-1 agonism works because it helps reduce appetite, improve satiety and support glucose control. That is the base mechanism underlying the first commercial wave and the starting point for all three stories here, directly or indirectly.

Viking’s VK2735 adds GIP to GLP-1. The practical reason investors care is that GLP-1/GIP dual agonism sits closer to the biology already validated by tirzepatide and by the broad market’s belief that combined incretin signaling can deliver stronger weight-loss and glycemic effects than GLP-1 alone. That can make Viking feel like a “closer substitute” for what big pharma has already proven.

Structure’s aleniglipron stays with GLP-1, but changes the route and chemistry. It is a non-peptide oral small molecule rather than a peptide injection. Commercially, oral small molecules matter because they may be easier for some patients to start, easier to combine with other oral agents, and potentially easier to scale industrially than peptide injectables — at least that is the thesis Structure itself emphasizes.

Altimmune’s pemvidutide pairs GLP-1 with glucagon. The appeal of glucagon is that it may increase energy expenditure and directly affect hepatic fat handling, which is why GLP-1/glucagon dual agonism is more naturally aligned with MASH and serious liver disease than pure obesity demand. The tradeoff is that glucagon-based differentiation can also introduce a more nuanced and less familiar narrative than the market’s standard GLP-1 playbook.

Clinical data comparison

These trials are not directly comparable. Viking’s reported obesity datasets are much shorter than Structure’s ACCESS II and Altimmune’s 48-week MASH follow-up, while Altimmune’s population is biopsy-confirmed MASH with fibrosis rather than a standard obesity registration-like cohort. Trial duration, baseline disease burden, diabetes mix, titration plan and endpoint handling differ materially.

Commercial landscape

The most important commercial fact in May 2026 is that smaller obesity biotechs are no longer chasing an empty field. Lilly already has Foundayo approved as an oral obesity therapy, and Novo already has the Wegovy pill approved and launched in the U.S. That means Structure is competing against marketed oral options, not just injectable incumbents. It also means Viking’s oral program, while interesting, would be entering a market where oral convenience is no longer unique.

This is why route alone should not drive investment conclusions. Oral drugs may still matter a great deal because they can lower initiation barriers, integrate well with telehealth or direct-to-patient channels, and address people who do not want injections. But the commercial questions now extend to pricing, adherence, discontinuation and manufacturability. Lilly is already explicitly marketing Foundayo around convenience and affordability, while Novo is promoting the Wegovy pill as providing injection-like efficacy in a daily pill form.

For Altimmune, the commercial frame is different again. Pemvidutide does not need to beat every obesity drug on pure weight loss to matter commercially if it can occupy a liver-metabolic niche that is genuinely differentiated. The company’s current strategy, FDA interactions and financing language all indicate that MASH is the lead value driver. That likely implies either disciplined standalone Phase 3 execution followed by strategic interest, or eventual partnership if Phase 3 evidence is strong enough.

Financial comparison

Financial table reflects the companies’ most recent verified disclosures available as of May 9, 2026. Altimmune had not yet reported Q1 2026 results as of May 9, 2026.

Catalyst calendar

Catalyst dates above reflect the latest official company language available as of May 9, 2026. Where companies narrowed or changed timing, the newest guidance is used.

Institutional, insider and analyst note

Institutional ownership and analyst target data deserve caution because those datasets are point-in-time sensitive, lagged across public reporting systems and often dependent on vendor aggregation rather than a single authoritative source. The clearest verifiable ownership signal is at Altimmune, where the April 2026 financing was led by specialist biotech investors including Deep Track Capital, TCGX, Viking Global Investors and RA Capital, and the IR filings page also shows a Schedule 13G filing on May 1, 2026. That is a sound place to stop rather than force a stale top-holder ranking.

Retail sentiment

Retail traders are watching three very different hooks. On Viking, the recurrent attraction is strategic optionality: Phase 3 execution, takeover speculation and the appeal of having both injectable and oral versions of the same dual-agonist molecule. On Structure, the hook is obvious: can aleniglipron become a serious oral obesity contender even after oral GLP-1 commercialization has already begun? On Altimmune, the debate is more polarized: bulls focus on MASH differentiation and partnership potential, while skeptics focus on dilution, warrants and whether the market will ever value pemvidutide as more than an interesting liver story. Those are interpretations of the current setup, not independently verified facts. The underlying factual drivers are the companies’ disclosed catalysts, clinical data and financing actions.

Bull, base and bear scenarios

Red flags

The first red flag across all three names is cross-trial comparison risk. These datasets differ too much in duration, population, endpoint selection and treatment assumptions to support simplistic rankings.

The second is commercial crowding. Oral obesity is already a real market, not a future one, and that raises the bar for both Structure and Viking’s oral strategy.

The third is tolerability and discontinuation. Viking’s oral discontinuation profile still deserves monitoring, Structure’s whole Phase 3 case depends on the lower starting dose fixing a known issue, and even Altimmune’s favorable discontinuation profile still needs confirmation in registrational MASH settings.

The fourth is financing and dilution. Viking’s burn has accelerated meaningfully; Structure is well funded now but later commercial costs remain outside current runway language; Altimmune has solved immediate funding pressure at the price of a more dilutive and warrant-heavy capital structure.

The fifth is execution. All three companies are now close enough to late-stage risk that timelines, protocol design, manufacturing readiness and regulatory clarity matter at least as much as scientific elegance.

Bottom line

If the market wants the most visible dual-agonist obesity biotech story, Viking is still the cleanest answer. If the market wants the purest oral obesity comparison, Structure remains the obvious candidate — but now in a world where oral obesity is already commercial, which raises the bar sharply. If the market wants the differentiated metabolic-liver angle, Altimmune is the most distinct name of the three.

The deeper takeaway is that this race is no longer simply about who can post the biggest body-weight reduction. The more durable questions are about route, titration, persistence, scalability, liver or cardiometabolic breadth, trial design, funding discipline and strategic optionality. That is why these three companies belong in the same discussion — and why they should not be valued as interchangeable “weight-loss stocks.”

None of the analysis above is a buy or sell recommendation. It is a way to understand what each company is actually trying to become in the post-first-wave obesity market of 2026.

Key uncertainties

A few points deserve caution. Altimmune had not yet reported first-quarter 2026 financial results as of May 9, 2026, so the latest verified operating numbers remain the March 2026 full-year update plus subsequent financing announcements. Comparable top-holder and consensus price-target data were not standardized enough across primary sources to justify a reliable ranking here. Most importantly, no head-to-head study among VK2735, aleniglipron and pemvidutide exists, and Altimmune’s lead active development frame is MASH/serious liver diseases rather than pure obesity, so mechanistic interpretation should not be confused with proof of superiority.

Current medicines: what patients and prescribers already have before VKTX, GPCR or ALT arrive

The current market is not one market. It is a stack. At the top of the stack are premium incretin medicines with strong efficacy and enormous brand power. Below that are older oral agents and short-term appetite suppressants that remain relevant because they are cheaper, familiar and easier to prescribe in some settings. Beside that stack are rare-obesity drugs such as setmelanotide, which do not compete for broad market share but show how genetic or disease-specific segmentation can still create value. In a separate but increasingly overlapping stack sits MASH, where Rezdiffra has changed the field from “no approved therapy” to “prove why your liver drug belongs beside or after resmetirom.”

The older obesity medicines matter because they reveal a practical truth: not every patient starts with the most powerful drug. Some start with what insurance covers. Some start with what a primary-care doctor already knows. Some start with a drug that is cheaper, even if it is less effective. Some patients cannot tolerate GLP-1 gastrointestinal effects. Some have contraindications. Some want a pill but do not want a premium-priced oral incretin. These realities create a lower-end market where medicines such as orlistat, phentermine/topiramate and naltrexone/bupropion still have commercial relevance. The NIDDK list of FDA-approved long-term weight-management drugs captures that older base: orlistat, phentermine-topiramate, naltrexone-bupropion, liraglutide, semaglutide and tirzepatide, with setmelanotide reserved for specific rare genetic obesity disorders. [4]

The blockbuster incretin layer matters for a different reason. Wegovy and Zepbound have trained physicians and patients to expect double-digit weight loss, chronic maintenance and broader cardiometabolic benefit. Zepbound’s FDA approval for chronic weight management in 2023, and later approval for obstructive sleep apnea in adults with obesity, are not just label facts; they are examples of how obesity drugs can expand into adjacent disease categories. That is one of the most important lessons for Altimmune. The most attractive metabolic drugs are no longer just weight-loss products. They are platforms that can move through sleep apnea, cardiovascular disease, kidney disease, liver disease, osteoarthritis and other obesity-linked conditions if the data support it. [5] [6]

The new oral incretin layer is where Structure and Viking’s oral program face the hardest test. Novo’s Wegovy pill and Lilly’s Foundayo make the oral category real. Novo’s release said oral semaglutide 25 mg showed 16.6% mean weight loss in the OASIS 4 trial when treatment was adhered to, and Lilly’s release said Foundayo produced 12.4% average weight loss at the highest dose among participants who stayed on treatment in ATTAIN-1. Those are different trials and should not be compared lazily, but they are enough to set a real-world expectation. The patient can now ask, “Why wait for another pill?” A future product must answer that question with data, price, dosing, tolerability, availability or combination logic. [3] [2]

The MASH layer is just as important for Altimmune. Rezdiffra’s FDA approval in March 2024 gave physicians the first approved direct treatment option for adults with noncirrhotic NASH/MASH with moderate to advanced fibrosis, used along with diet and exercise. The EMA has also described Rezdiffra’s benefit in MASH and liver fibrosis, with the active substance resmetirom activating THR-beta in liver cells to increase fat breakdown. That matters because pemvidutide must now prove not only that it can improve liver markers, but that it can justify use in a field where a liver-targeted oral medicine already exists. If pemvidutide shows a broader metabolic-liver package, the competition can validate the market. If it does not, Rezdiffra becomes the reference standard that narrows the case. [7] [8]

Detailed medicine-by-medicine implications

Wegovy injection, Wegovy HD and Wegovy pill. Novo’s semaglutide franchise matters because it has brand trust, prescriber familiarity and multiple dosage forms. The injection created the modern obesity-drug wave, the higher-dose Wegovy HD approval gives Novo another efficacy lever in adults, and the pill changes the access and convenience story. For Viking, this means oral VK2735 has to show why an oral dual agonist can be better or more flexible than an oral GLP-1, while injectable VK2735 has to compete against a semaglutide franchise that keeps evolving. For Structure, it means aleniglipron’s efficacy has to be judged against a product that is already approved and built on a familiar molecule. For Altimmune, semaglutide matters indirectly because any GLP-1 with liver or cardiometabolic evidence can compete for metabolically complicated patients.

Zepbound and Mounjaro. Tirzepatide is the strongest commercial validation of GLP-1/GIP dual agonism. That is helpful for Viking because VK2735 uses a related dual-incretin concept. It is also threatening because Lilly already owns the commercial category leader. Viking does not have to beat tirzepatide in every dimension to have value, but it must show enough differentiation to justify attention. Possibilities include oral optionality, maintenance dosing, cleaner tolerability or strategic fit for a larger company that needs a dual-incretin competitor.

Foundayo. Foundayo is the most important direct competitive medicine for Structure. Lilly’s claim that Foundayo can be taken at any time without food or water restrictions is commercially powerful because dosing burden matters in chronic daily therapy. Structure’s aleniglipron may have stronger Phase 2 efficacy signals, but Phase 3 must prove that those signals survive a larger, longer, more commercially relevant study design. If aleniglipron requires complicated titration or has meaningful discontinuation, Foundayo’s simpler positioning could matter even if headline weight loss is lower.

Older oral drugs. Qsymia, Contrave/Mysimba, orlistat and short-term appetite suppressants do not look like modern GLP-1 competitors on efficacy, but they matter because they anchor the low-cost end of the market. Payers can use them in step therapy. Physicians can prescribe them when incretins are unavailable or unaffordable. Patients can choose them when cost dominates. This creates a pricing umbrella problem: premium incretin drugs can command value, but only if they continue to prove that their outcomes justify the cost.

Imcivree. Setmelanotide does not compete for general obesity. Its importance is strategic, not market-share-based. It shows that obesity can be segmented by biology. That lesson applies to Altimmune most obviously, because MASH is a disease-defined segment, but it also applies to Viking and Structure if future data define subgroups such as diabetes, maintenance, oral-switch patients, or patients with certain comorbidity clusters.

Rezdiffra. Rezdiffra is not an obesity medicine, but it is highly relevant to Altimmune’s case because pemvidutide is currently a MASH and serious-liver-disease story. Rezdiffra creates a liver-specialist benchmark. Pemvidutide’s glucagon/GLP-1 biology may offer a broader metabolic approach, but Phase 3 has to turn that theory into biopsy and clinically meaningful evidence. The bar in MASH is not simply liver fat reduction. The bar is resolution, fibrosis, durability, tolerability and eventually clinical outcomes.

Competitive impact: a scenario model

The following scenarios help estimate how the new competition could change each company’s future. These are not price targets, probability tables or revenue forecasts. They are practical narratives for interpreting future catalysts.

Scenario 1: the incumbents keep widening the gap

In this scenario, Lilly and Novo continue to dominate with injections, oral products, lower net prices, direct-to-consumer access and larger comorbidity labels. Retatrutide, CagriSema, CT-388 and other large-company or large-company-backed programs raise the efficacy ceiling. Payers become more aggressive because the patient population is enormous. Net prices fall. Physicians become less willing to try unproven late entrants unless the clinical story is clearly superior.

For Viking, this scenario is challenging unless Phase 3 data are excellent. A good-but-not-great VK2735 could struggle to command excitement if Zepbound, Wegovy, Foundayo, Wegovy pill and future products already occupy the main lanes. Viking would still have strategic value, but probably more as a partner or acquisition candidate than as an obvious standalone commercial winner.

For Structure, this scenario is the toughest. The oral market expands, but Lilly and Novo take the first wave. Aleniglipron would need either better efficacy, better adherence, better cost or a strong partner to avoid being viewed as late. The company’s cash runway helps, but commercial scale remains a separate question.

For Altimmune, this scenario is survivable if MASH data are strong. Incumbent obesity dominance does not automatically defeat a liver-focused asset. However, if Lilly and Novo move strongly into MASH with their own incretin portfolios, pemvidutide would need very clean differentiation.

Scenario 2: oral therapy expands the whole market

In this scenario, oral GLP-1s do not merely cannibalize injections; they bring in new patients. Primary-care physicians become more comfortable prescribing obesity medicines. Needle-averse patients enter therapy. Telehealth and direct channels grow. Manufacturing constraints ease because oral small molecules or tablets can scale differently than injectable peptides. The market becomes larger, even if average net prices fall.

This scenario helps Structure the most. It validates the entire oral-small-molecule thesis. Even with Foundayo and Wegovy pill already approved, a best-in-class or near-best-in-class aleniglipron could find space if the oral segment becomes large enough. It also helps Viking’s oral program if oral VK2735 can be positioned as a dual-incretin alternative or a maintenance option. It helps Altimmune indirectly by increasing the number of treated metabolic patients and likely improving screening for liver disease.

The risk in this scenario is that category expansion can hide share compression for a while. Investors may see a huge total addressable market and underestimate how hard it is to win reimbursement, patient persistence and physician mindshare. A huge market with falling prices can still be difficult for late entrants.

Scenario 3: MASH becomes the next major metabolic battleground

In this scenario, obesity treatment increasingly merges with liver treatment. More obese and diabetic patients are screened for MASLD/MASH. Hepatologists and endocrinologists collaborate more often. Rezdiffra expands awareness. GLP-1, GLP-1/GIP, GLP-1/glucagon and FGF21 programs compete for different liver-metabolic profiles.

This scenario helps Altimmune most. Pemvidutide’s rationale becomes more understandable if investors stop asking it to beat Zepbound on simple weight loss and start asking whether it can treat a liver-metabolic phenotype. It also gives Viking and Structure optional future lanes if their assets produce credible liver or metabolic-comorbidity data, but neither is as liver-centered as Altimmune today.

The risk is that MASH is clinically and commercially difficult. Diagnosis remains a bottleneck. Biopsy and non-invasive testing pathways are evolving. Payers may require evidence of fibrosis stage. Long-term outcomes take time. A promising Phase 2 MASH asset can still fail to translate cleanly into Phase 3.

Scenario 4: pricing pressure becomes the dominant story

In this scenario, the obesity-drug market grows in unit volume but net pricing falls faster than investors expected. Direct self-pay prices, government agreements, employer benefit redesign and payer restrictions compress revenue per patient. Persistence improves only partly. Patients cycle on and off therapy. The market remains huge, but margins and revenue forecasts become less spectacular.

This scenario is a problem for every pure obesity story. Viking would need either high strategic value or a differentiated maintenance angle. Structure would need small-molecule manufacturing and oral convenience to translate into real economic advantage. Altimmune could be partially insulated if MASH pricing and specialist use support a different reimbursement model, but only if Phase 3 evidence is strong enough.

How to read the next catalysts

Catalysts in this sector should be read through competitive context, not in isolation. A data release can look strong by itself and still fail commercially if it does not clear the current market bar. That is especially true for Phase 2 obesity trials, where study duration, baseline BMI, diabetes status, dose escalation and discontinuation handling can change interpretation.

For Viking, the maintenance-dosing study is more important than it may look. If the data support less frequent maintenance, Viking gains a differentiating lever. The oral Phase 3 start is also important because it shows whether the company can move the tablet program forward despite a more crowded oral field. The Phase 3 VANQUISH program remains the core value driver, but maintenance and oral optionality shape the strategic premium around that core.

For Structure, the ACCESS OLE, body-composition, type 2 diabetes/obesity and switch-study data matter because they address the questions that headline weight-loss percentages do not answer. Can patients stay on aleniglipron? Does lower starting dose meaningfully fix discontinuation? What happens to lean mass and fat mass? Can patients switch from an injectable GLP-1 to oral aleniglipron for maintenance? Can the drug work in type 2 diabetes populations? These questions are directly commercial.

For Altimmune, the most important issue is Phase 3 MASH execution. The April 2026 financing reduced near-term funding anxiety but added dilution and warrant complexity. That means the stock needs clinical and operational confidence. Phase 3 initiation, trial design clarity, biopsy endpoints, dose selection, use of non-invasive markers and any partnership signals will matter more than obesity-sector hype.

Company conclusions

Viking Therapeutics: the strategic asset must become a differentiated product

Viking has the clearest late-stage obesity asset among the three. That alone is valuable. Subcutaneous VK2735 is already in Phase 3, and the oral version gives Viking a second path. But the company is no longer evaluated against empty space. It is evaluated against Zepbound, Wegovy, Wegovy pill, Foundayo and future next-generation programs. That means Viking’s best outcome is not just a strong Phase 3 readout; it is a strong Phase 3 readout plus a believable product strategy.

The most attractive Viking story is a dual-formulation ecosystem. A patient could start with injectable therapy for induction, transition to a maintenance schedule, or potentially move to an oral formulation if the data and label allow. This is not guaranteed, but it is the kind of commercial idea that can still stand out. The bear version is that VK2735 works, but not uniquely enough, while development costs rise and incumbents keep moving.

Structure Therapeutics: oral validation is both blessing and curse

Structure has one of the cleanest oral stories in biotech. Aleniglipron’s ACCESS II result is strong enough to matter, and the company’s cash position is unusually robust for a clinical-stage challenger. But oral validation by Novo and Lilly means Structure cannot rely on novelty. It must rely on performance.

The most attractive Structure story is an oral small-molecule platform that can produce injectable-like efficacy with practical titration and future combination flexibility. That could be commercially powerful, especially outside the U.S. or in primary-care settings. The bear version is that aleniglipron reaches Phase 3 as a good oral GLP-1 in a market where good oral GLP-1s already exist. In that case, the asset may still have value, but the premium narrative fades.

Altimmune: the obesity label is too narrow for the thesis

Altimmune should not be judged as a simple weight-loss stock. Pemvidutide’s current value is tied to MASH and serious liver disease. Its glucagon component is not just a mechanistic flourish; it is the reason the asset may be different. The problem is that MASH is a demanding field, and the company has had to finance heavily to reach the next stage.

The most attractive Altimmune story is a Phase 3-ready MASH asset with metabolic benefit, liver-fat reduction, fibrosis-marker improvement and low discontinuation. The bear version is that Phase 2 non-invasive marker strength does not translate into definitive Phase 3 biopsy or clinical benefit, while dilution limits upside. The company has the most differentiated biology in this trio, but also the least direct path to a mass obesity narrative.

Final ranking by strategic clarity

A simple “best stock” ranking would be misleading. These are different risk instruments. But they can be ranked by strategic clarity.

Most straightforward obesity-development story: Viking. The asset is in Phase 3, the mechanism is commercially validated by tirzepatide, and the oral-plus-injectable strategy gives the company optionality. The main issue is whether the asset is differentiated enough and whether the company can fund and execute late-stage development without losing strategic leverage.

Most direct oral-obesity challenger: Structure. Aleniglipron is the purest oral-small-molecule bet among the three. The data are strong, the balance sheet is strong, and the competitive question is brutally clear: can it beat or segment around approved oral GLP-1 products?

Most differentiated metabolic-liver angle: Altimmune. Pemvidutide is not a clean obesity stock, but it is the most distinct MASH story in this trio. Its upside depends on the liver-metabolic thesis, not on winning a headline obesity percentage race.

What could change the view quickly

For Viking, a surprisingly strong maintenance-dosing result could make the product strategy more compelling before Phase 3 efficacy data arrive. Conversely, any delay in oral Phase 3 or signs of tolerability problems could weaken the dual-formulation story.

For Structure, the most important near-term upgrade would be confirmation that the 2.5 mg starting dose materially lowers discontinuations while preserving strong weight loss. The most important downgrade would be Phase 3 design uncertainty or evidence that tolerability management requires too much compromise.

For Altimmune, a sharper Phase 3 MASH start timeline, clean regulatory design and partnership interest would strengthen confidence. Any sign that financing pressure, warrant overhang or MASH trial complexity is slowing execution would weaken the thesis.

Closing view

The next obesity-drug race is no longer a race to prove that incretins work. That race is over. The new race is to prove that a product can matter after the category has already been commercialized. Viking, Structure and Altimmune all still have plausible paths, but none has an easy path. Viking must turn a promising dual agonist into a differentiated late-stage franchise. Structure must turn oral efficacy into commercially superior oral therapy. Altimmune must turn liver-metabolic differentiation into registrational MASH value.

That is the shape of the sector in May 2026: enormous market, enormous need, enormous competition. The winners will not be the companies with the best slogan. They will be the companies whose data answer the specific question the market is now asking: why this drug, for this patient, at this price, in this treatment sequence, after the first GLP-1 wave has already arrived?

Sources and further reading

1. U.S. Food and Drug Administration, “FDA Approves First New Molecular Entity Under National Priority Voucher Program,” April 1, 2026. Source
2. Eli Lilly and Company, “FDA approves Lilly’s Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions,” April 1, 2026. Source
3. Novo Nordisk, “Wegovy® pill approved in the US as first oral GLP-1 for weight management,” December 22, 2025. Source
4. National Institute of Diabetes and Digestive and Kidney Diseases, “Prescription Medications to Treat Overweight & Obesity,” accessed May 2026. Source
5. U.S. Food and Drug Administration, “FDA Approves New Medication for Chronic Weight Management,” November 8, 2023. Source
6. U.S. Food and Drug Administration, “FDA Approves First Medication for Obstructive Sleep Apnea,” December 20, 2024. Source
7. U.S. Food and Drug Administration, “FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease,” March 14, 2024. Source
8. European Medicines Agency, “Rezdiffra,” EPAR medicine overview. Source
9. Viking Therapeutics, “Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update,” April 29, 2026. Source
10. Viking Therapeutics, “Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity,” August 19, 2025. Source
11. Structure Therapeutics, “Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron,” March 16, 2026. Source
12. Structure Therapeutics, “Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights,” May 7, 2026. Source
13. Altimmune, “Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial,” December 19, 2025. Source
14. Altimmune, “Altimmune Announces Positive Topline Results from the IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH,” June 26, 2025. Source
15. Altimmune, “Altimmune Announces Closing of $225 Million Oversubscribed Public Offering of Securities,” April 27, 2026. Source
16. Eli Lilly and Company, “Lilly reports first-quarter 2026 financial results, raises full-year guidance, and highlights momentum of new medicines,” April 30, 2026. Source
17. Morgan Stanley Research, “Obesity Drugs Are Scaling Fast,” April 22, 2026. Source
18. Reuters, “Obesity market sales potential tightens as Novo and Lilly enter new era,” February 2, 2026. Source
19. Reuters, “Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030,” January 14, 2026. Source
20. Roche, “Roche announces positive Phase II results for obesity drug CT-388,” January 27, 2026. Source
21. Eli Lilly and Company, “Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine,” June 26, 2023. Source
22. European Medicines Agency, “Wegovy,” EPAR medicine overview. Source
23. European Medicines Agency, “Mounjaro,” EPAR medicine overview. Source
24. European Medicines Agency, “Mysimba,” EPAR medicine overview. Source
25. U.S. Food and Drug Administration, “FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide,” March 19, 2026. Source
26. Altimmune, “Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA and Updated Guidance for Pemvidutide Phase 3 Obesity Program,” November 7, 2024. Source
27. Altimmune, “Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH,” January 5, 2026. Source
28. Altimmune, Form 10-K for the year ended December 31, 2025, filed with the SEC. Source